Anne C. Moorman

Anne C. Moorman

Auto-generated profile, based on publicly available information

Anne C. Moorman

Centers for Disease Control and Prevention

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 1998 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
FPFrank J. Jr. Palella
Frank J. Jr. Palella
KDKathleen M. Delaney
Kathleen M. Delaney
AMAnne C. Moorman
Anne C. Moorman
MLMark O. Loveless
Mark O. Loveless
JFJack Fuhrer
Jack Fuhrer
TIthe HIV Outpatient Study Investigators
the HIV Outpatient Study Investigators
National surveillance data show recent, marked reductions in morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS). To evaluate these declines, we analyzed data on 1255 patients, each of whom had at least one CD4+ count below 100 cells per cubic millimeter, who were seen at nine clinics specializing in the treatment of human immunodeficiency virus (HIV) infection in eight U.S. cities from January 1994 through June 1997. Mortality among the patients declined from 29.4 per 100 person-years in 1995 to 8.8 per 100 person-years in the second quarter of 1997. There were reductions in mortality regardless of sex, race, age, and risk factors for transmission of HIV. The incidence of any of three major opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium complex disease, and cytomegalovirus retinitis) declined from 21.9 per 100 person-years in 1994 to 3.7 per 100 person-years by mid-1997. In a failure-rate model, increases in the intensity of antiretroviral therapy (classified as none, monotherapy, combination therapy without a protease inhibitor, and combination therapy with a protease inhibitor) were associated with stepwise reductions in morbidity and mortality. Combination antiretroviral therapy was associated with the most benefit; the inclusion of protease inhibitors in such regimens conferred additional benefit. Patients with private insurance were more often prescribed protease inhibitors and had lower mortality rates than those insured by Medicare or Medicaid. The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.

1 September 2006 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
FPFrank J Palella
Frank J Palella
RBRose K Baker
Rose K Baker
AMAnne C Moorman
Anne C Moorman
JCJoan S Chmiel
Joan S Chmiel
KWKathleen C Wood
Kathleen C Wood
HIHIV Outpatient Study Investigators
HIV Outpatient Study Investigators
AIDS-related death and disease rates have declined in the highly active antiretroviral therapy (HAART) era and remain low; however, current causes of death in HAART-treated patients remain ill defined. To describe mortality trends and causes of death among HIV-infected patients in the HAART era. Prospective, multicenter, observational cohort study of participants in the HIV Outpatient Study who were treated from January 1996 through December 2004. Rates of death, opportunistic disease, and other non-AIDS-defining illnesses (NADIs) determined to be primary or secondary causes of death. Among 6945 HIV-infected patients followed for a median of 39.2 months, death rates fell from 7.0 deaths/100 person-years of observation in 1996 to 1.3 deaths/100 person-years in 2004 (P = 0.008 for trend). Deaths that included AIDS-related causes decreased from 3.79/100 person-years in 1996 to 0.32/100 person-years in 2004 (P = 0.008). Proportional increases in deaths involving liver disease, bacteremia/sepsis, gastrointestinal disease, non-AIDS malignancies, and renal disease also occurred (P = <0.001, 0.017, 0.006, <0.001, and 0.037, respectively.) Hepatic disease was the only reported cause of death for which absolute rates increased over time, albeit not significantly, from 0.09/100 person-years in 1996 to 0.16/100 person-years in 2004 (P = 0.10). The percentage of deaths due exclusively to NADI rose from 13.1% in 1996 to 42.5% in 2004 (P < 0.001 for trend), the most frequent of which were cardiovascular, hepatic, and pulmonary disease, and non-AIDS malignancies in 2004. Mean CD4 cell counts closest to death (n = 486 deaths) increased from 59 cells/μL in 1996 to 287 cells/μL in 2004 (P < 0.001 for trend). Patients dying of NADI causes were more HAART experienced and initiated HAART at higher CD4 cell counts than those who died with AIDS (34.5% vs 16.8%, respectively, received HAART for 4 of more years, P < 0.0001; 22.4% vs 7.8%, respectively, initiated HAART with CD4 cell counts of more than 350 cells/μL, P < 0.001). Although overall death rates remained low through 2004, the proportion of deaths attributable to non-AIDS diseases increased and prominently included hepatic, cardiovascular, and pulmonary diseases, as well as non-AIDS malignancies. Longer time spent receiving HAART and higher CD4 cell counts at HAART initiation were associated with death from non-AIDS causes. CD4 cell count at time of death increased over time.

20 May 2008 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
PPPragna Patel
Pragna Patel
DHDebra L. Hanson
Debra L. Hanson
PSPatrick S. Sullivan
Patrick S. Sullivan
RNRichard M. Novak
Richard M. Novak
AMAnne C. Moorman
Anne C. Moorman
FIfor the Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators*
for the Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators*
Persons who are HIV-infected may be at higher risk for certain types of cancer than the general population. To compare cancer incidence among HIV-infected persons with incidence in the general population from 1992 to 2003. Prospective observational cohort studies. United States. 54 780 HIV-infected persons in the Adult and Adolescent Spectrum of HIV Disease Project (47 832 patients) and the HIV Outpatient Study (6948 patients), who contributed 157 819 person-years of follow-up from 1992 to 2003, and 334 802 121 records from the Surveillance, Epidemiology, and End Results program of 13 geographically defined, population-based, central cancer registries. Standardized rate ratios (SRRs) to compare cancer incidence in the HIV-infected population with standardized cancer incidence in the general population. The incidence of the following types of non–AIDS-defining cancer was significantly higher in the HIV-infected population than in the general population: anal (SRR, 42.9 [95% CI, 34.1 to 53.3]), vaginal (21.0 [CI, 11.2 to 35.9]), Hodgkin lymphoma (14.7 [CI, 11.6 to 18.2]), liver (7.7 [CI, 5.7 to 10.1]), lung (3.3 [CI, 2.8 to 3.9]), melanoma (2.6 [CI, 1.9 to 3.6]), oropharyngeal (2.6 [CI, 1.9 to 3.4]), leukemia (2.5 [CI, 1.6 to 3.8]), colorectal (2.3 [CI, 1.8 to 2.9]), and renal (1.8 [CI, 1.1 to 2.7]). The incidence of prostate cancer was significantly lower among HIV-infected persons than the general population (SRR, 0.6 [CI, 0.4 to 0.8]). Only the relative incidence of anal cancer increased over time. Lower ascertainment of cancer in the HIV cohorts may result in a potential bias to underestimate rate disparities. Tobacco use as a risk factor and the effect of changes in cancer screening practices could not be evaluated. The incidence of many types of non–AIDS-defining cancer was higher among HIV-infected persons than among the general population from 1992 to 2003.

1 November 2002 in The Lancet
Verified
Journal Article
Closed access
SHScott D Holmberg
Scott D Holmberg
AMAnne C Moorman
Anne C Moorman
JWJohn M Williamson
John M Williamson
TTTony C Tong
Tony C Tong
DWDouglas J Ward
Douglas J Ward
HIHIV Outpatient Study (HOPS) investigators
HIV Outpatient Study (HOPS) investigators

1 July 2001 in AIDS
Verified
Journal Article
Closed access
KLKenneth A. Lichtenstein
Kenneth A. Lichtenstein
DWDouglas J. Ward
Douglas J. Ward
AMAnne C. Moorman
Anne C. Moorman
KDKathleen M. Delaney
Kathleen M. Delaney
BYBenjamin Young
Benjamin Young
SHScott D. Holmberg
Scott D. Holmberg
To identify clinical factors associated with prevalence of fat atrophy (lipoatrophy) and fat accumulation (lipoaccumulation) in HIV-1 infected patients. Evaluation of HIV-1 infected patients seen for routine care between 1 October and 31 December 1998 in the eight HIV Outpatient Study (HOPS) clinics. Eight clinics specializing in the care of HIV-1 infected patients. A total of 1077 patients were evaluated for signs of fat maldistribution. A standardized set of questions and specific clinical signs were assessed. Demographic, clinical and pharmacological data for each patient were also included in the analysis. Demographic, immunologic, virologic, clinical, laboratory, and drug treatment factors were assessed in stratified and multivariate analyses for their relationship to the presence and severity of fat accumulation and atrophy. Independent factors for moderate/severe lipoatrophy for 171 patients were increasing age, any use of stavudine, use of indinavir for longer than 2 years, body mass index (BMI) loss, and measures of duration and severity of HIV disease. Independent risk factors for moderate/severe fat accumulation for 104 patients were increasing age, BMI gain, measures of amount and duration of immune recovery, and duration of antiretroviral therapy (ART). The number of non-drug risk factors substantially increased the likelihood of lipoatrophy. If non-drug risk factors were absent, lipoatrophy was unusual regardless of the duration of drug use. HIV-associated lipodystrophy is associated with several host, disease, and drug factors. While prevalence of lipoatrophy increased with the use of stavudine and indinavir, and lipoaccumulation was associated with duration of ART, other non-drug factors were strongly associated with both fat atrophy and accumulation.

16 May 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
SHScott D. Holmberg
Scott D. Holmberg
PSPhilip R. Spradling
Philip R. Spradling
AMAnne C. Moorman
Anne C. Moorman
MDMaxine M. Denniston
Maxine M. Denniston
Recent analyses suggest that of the estimated 3.2 million people infected with hepatitis C virus, only about half have been tested and know their status, about a third have been referred for HCV care, and only 5 to 6% have been successfully treated.